Biotech
Merck’s cancer drug Keytruda approved quickly after proven effective against tumors
Keytruda, a cancer drug developed by Merck & Co, was able to notably shrink the tumors of 48 out of 88 patients. Another 18 saw their tumors gone.
A small study involving Keytruda (pembrolizumab) showed that the cancer drug has been effective in shrinking or removing cancer tumors. With this, the U.S. Food and Drug Administration immediately approved the drug for patients with locally advanced or metastatic urothelial carcinoma.
The Keytruda is the first drug that has been approved for treating tumors that share a certain genetic profile, and thousands of patients are expected to benefit from it every year, according to The New York Times. Even without a control group, or a set of patients that did not receive the drug to compare with, the results are compelling and convincing.
The study, originally released in the Science journal, saw eighty-six patients participating in the trial. Sixty-six of them had tumors that shrank significantly. Among the 66 patients, 18 patients had their tumors disappeared.
Is Keytruda the answer to the cancer battle? (Source)
Dr. Jack Jacoub, a medical oncologist at MemorialCare Cancer Institute, said that the results of the study, which was published in the journal Science last week, showed the effectiveness of targeting the immune system to treat cancer. This is in contrast to the common classification of cancers based on their location in the body. With pembrolizumab, the cancer cells are unmasked so that the immune system can identify and destroy them.
Keytruda is made by Merck & Co. and costs around $156,000 a year for patients with advanced lung, melanoma and bladder tumors. The study is ongoing, and the drug maker has also begun a trial to pair Keytruda with CTLA4 candidate MK-1308, per FiercePharma.
Merck hosted an encouraging analyst meeting at ASCO last week, and Morgan Stanley remains bullish on growth prospects of its new cancer drug. The Keytruda is the main catalyst for the company’s stock this year, which Zacks Investment Research rated “buy” in a research note published on May 26, according to a report from Smart Stock News.
Fintech Company Sonect Wants to Supply Europe with Cash
As ATM numbers decline, Swiss fintech Sonect enables cash withdrawals at kiosks, stores, and cafés, creating “virtual ATMs.” Operating over...
Why Ethereum Researchers Withdraw from EigenLayer
Ethereum researchers Ryan and Drake stepped down from EigenLayer, returning unvested tokens to prevent conflicts of interest. EigenLayer enables Ethereum...
ClubDeal Digital Contributes to Flyted’s Closing of the First Phase of its Series A Round
Flyted secured its first €1 million funding round to strengthen its infrastructure inspection services, supported by ClubDeal Digital’s platform, which...
Fighting Agri-Food Fraud: How TecnoCientifica’s T-Scanner is Changing the Game
Agri-food fraud is estimated to cost anywhere from $30-40 billion annually. Often involving passing off inferior products as premium products,...
Gold and S&P 500 Hit Historic Highs in a Race for the Century’s Top Spot
The U.S. economy has been the envy of the world, but trouble lurks. The October jobs report was well below...
 |
|
 |  |
 |
|
-
Fintech2 weeks agoFintech Company Movizzon Launches in Spain to Expand Its Business in Europe
-
Business3 days agoTopRanked.io Weekly Affiliate Digest: What’s Hot in Affiliate Marketing [Parimatch Affiliates Review]
-
Cannabis2 weeks agoWhy the Dutch Are Growing Less and Less Cannabis: Four Times Fewer Plantations in 2023 than in 2019
-
Cannabis1 week agoEuropean Commission Launches Investigation into Italy’s CBD and Hemp Flower Ban
You must be logged in to post a comment Login